Mindstrong Health
Takeda’s zasocitinib shows high rates of skin clearance in phase 3 psoriasis studies
Globally, an estimated 64 million people have psoriasis, with about 80-90% of those having plaque psoriasis
Lilly to acquire AtaiBeckley in deal worth $2.8bn
The acquisition will advance therapies for treatment-resistant depression and other mental health conditions
Takeda’s new study data for oveporexton shows improvements in narcolepsy type 1
The phase 3 results show improvements in daily function, cognition and nighttime sleep
Takeda’s zasocitinib demonstrates positive results in plaque psoriasis
Around 64 million people worldwide live with psoriasis
La Roche-Posay launches global campaign to spotlight the visible and invisible impact of scars
‘Scars of Life’ aims to raise awareness of the psychological burden associated with skin conditions and scarring
From Burnout to Balance: New Campaign Focuses on the ‘Matters’ that are Really Affecting Our ‘Minds’ in Health Communications
Launched on World Mental Health Day, Minds on Matters aims to highlight mental wellbeing challenges while showcasing practical solutions and positive change
BMS, Takeda and Astex join AI training consortium
The initiative focuses on training AI models to aid in drug discovery and development
Takeda receives EC approval for Adcetris combination in Hodgkin lymphoma
The decision marks the second approval for an Adcetris-based regimen for front-line Hodgkin lymphoma
Takeda’s Adzynma approved by MHRA for rare blood clotting disorder cTTP
The enzyme replacement therapy is now the first treatment approved in the UK for this patient population
Takeda receives CHMP recommendation for Adcetris in Hodgkin lymphoma
The EC will review the committee’s positive opinion as it makes a decision on Adcetris in this indication
Takeda receives NICE recommendation for Adcetris combination in Hodgkin lymphoma
Around 800 people in the UK are diagnosed with late-stage disease every year
Takeda/Protagonist share positive phase 3 results for rusfertide in rare blood cancer
Up to 160,000 people in the US are affected by polycythaemia vera